Andere Sprachen BioCryst Pharmaceuticals, Inc.

Aktien

896047

US09058V1035

BCRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
4.16 ^USD	0.00%		-6.09%	-30.55%

17.04.	BioCryst Pharmaceuticals, Inc. gibt die Zulassung von ORLADEYO (Berotralstat) durch die brasilianische Gesundheitsbehörde bekannt	CI
12.03.	Transcript : BioCryst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioCryst to Report First Quarter 2024 Financial Results on May 6	22.04.
BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil	17.04.
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency	17.04.
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	17.04.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03.04.
BioCryst to Present at Upcoming Investor Conferences	25.03.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05.03.
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases	26.02.
BioCryst: Q4 Earnings Snapshot	26.02.
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.02.
Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q4 Revenue $93.4M, vs. Street Est of $90M	26.02.
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones	26.02.
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024	26.02.
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26.02.
North American Morning Briefing : Traders Await Inflation Data This Week	26.02.
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment	23.02.
BioCryst to Present at Upcoming Investor Conferences	21.02.
BioCryst Launches Hereditary Angioedema Drug in Italy	20.02.
BioCryst Launches ORLADEYO® (berotralstat) in Italy	19.02.
BioCryst Launches Orladeyo (Berotralstat) in Italy	19.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioCryst Pharmaceuticals, Inc.

Aktien

896047

US09058V1035

BCRX

Andere Sprachen

Filter